Kornimate/medical-research-clean huggingface dataset:
influence of laparoscopic endometrioma stripping surgery on serum anti-mullerian hormone levels

Conditions: Endometriosis

Summary: to compare changes in follicular ovarian reserve in women before and six months after laparoscopic operation: endometrioma stripping surgery. also, to compare follicular ovarian reserve in women with endometrioma(s) with follicular ovarian reserve of healthy infertile women of the same age group.

in order to investigate the impact of laparoscopic stripping surgery on follicular ovarian reserve, blood samples will be obtained before the operation, from 2nd to 5th day of the menstrual cycle, to determine levels of endocrine markers of ovarian reserve (fsh, e2, amh and inhibin b). cancer antigen 125 (ca -125) and il-6 will be measured also. us markers (antral follicular count- afc) will be obtained at the same time as endocrine markers. all laparoscopic stripping surgery will be performed during the early or middle follicular phases of menstrual cycle, under general anesthesia, by the same team of gynecological endoscopist. the cyst wall will be completely stripped off from the normal ovarian tissue by traction and opposite traction with two grasping forceps. hemostasis will be achieved using bipolar forceps electrocoagulation. all endometrioma specimens that will be obtained from operation will be submitted for pathology examination. one and six months after the laparoscopic cystectomy, from 2nd to 5th day of menstrual cycle, we will determine endocrine markers of ovarian reserve and levels of ca 125 and il-6. the control group will be consisted of healthy women with infertility problem. from the second to the fifth day of the menstrual cycle we will take blood samples to determinate endocrine markers of follicular ovarian reserve: amh, fsh, e2, inhibin b.

Eligibility criteria:
inclusion criteria:study group: women with endometrioma(s) * age: 18- 42 years of age * regular menstrual cycles defined as cycle length between 25- 35 days * ultrasound made diagnosis of endometrioma unilateral or bilateral ≥4 cm in diameter. * laparoscopically and histologically confirmed diagnosis. * agreement to be enrolled in the study control group: healthy reproductive aged women with tubal, unexplained or male infertility. - exclusion criteria: * previous ovarian surgery * suspicious of malignancy * known endocrine disorder or other chronic diseases. * use of oral contraceptive drug, gonadotropin- releasing hormone (gnrh) agonist/ antagonist, or other drugs related with ovarian function in at least 3 months before surgery.

Keywords: endometrioma laparoscopy ovarian reserve
omega-3 fatty acid supplementation and tear film quality in celiac patients

Conditions: Dry Eye Syndromes; Celiac Disease

Summary: the study aims to determine the effectiveness on the tear film quality and symptoms related with dry eye disease in patients with celiac disease.

patients diagnosed with celiac disease will be recruited for the study. they will be randomly assigned to one of the three arms (intervention group 1 - high dose epa and dha, intervention group 2 - low dose epa and dha, or control - extra virgin olive oil) and for 45 days take supplementation as instructed. during the intervention they will be instructed to maintain their diet and lifestyle (i.e. they will not receive any education on diet or lifestyle modification). at inclusion, patients will complete one basic questionnaire on sociodemographic data, one questionnaire which assess accidental exposure to gluten and their weight and height will be measured. subjective symptoms related to dry eye disease will be assessed with ocular surface disease index (osdi) test, while quality and quantity of the tear film will be assessed with the schirmer's test i and tear break-up time test (tbut). dietary intake of omega-3 acids will be controlled by one 24-hour dietary recall (completed at inclusion an after the intervention).

Eligibility criteria:
inclusion criteria: * diagnosis of celiac disease * signed informed consent form exclusion criteria: * use of medications for diabetes, hypertension, depression, thyroid disease, allergies, epilepsy, psychosis, glaucoma * use of oral contraceptive pills * alcoholism or use of alcohol on the day of recruitment * menopause * eye trauma or surgery in the past 3 months * wearing contact lens * supplementation with omega-3 fatty acids regardless of the dose used in the past month * not understanding bosnian letter or language * informed consent form not signed

Keywords: celiac disease supplementation omega-3 fatty acids dry eye syndromes
efficacy of azadirachta indica based herbal mouthwash in treating the tooth hypersensitivity

Conditions: Tooth Sensitivity

Summary: type of study: single-blinded clinical trial to evaluate the effectiveness of azadirachta indica based herbal mouthwash to treat the tooth sensitivity in patients. participants aged 20 years and above having gingival index score 3 will be included in the study. their tooth sensitivity will be checked initially and then they will be given herbal based mouthwash for 3 months. again, their tooth sensitivity shall be checked after 3 months.

in this study herbal based mouthwash will be evaluated for eliminating the tooth sensitivity in the participants having gingival index score 3 with vas scores for sensitivity ranging between 30-80 . consecutive non-random sampling technique will be used in this study where participants included will be assessed for tooth sensitivity through visual analogue scale (vas) initially for base line readings. these participants will be given azadirachta indica based herbal mouthwash for three months and then again their tooth sensitivity will be assessed by visual analogue scale (vas) for final readings. the mean values of vas scoring both before and after the usage of herbal mouth wash will be compared to investigate the clinical efficacy of this mouthwash in treating the tooth sensitivity.

Eligibility criteria:
inclusion criteria: * patients with good general health and no allergy * patients who have not used any mouthwash in last 3 month * study teeth shall be free of decay and restoration * study teeth shalll not be mobile * study teeth shall have the gingival index score 3 * participants shall be able to read ,write and willing to give consent. exclusion criteria: * patients with poor general health and allergies * patients who have used any mouthwash in last 3 months * teeth with decay and restorations * teeth with mobility * teeth with gingival index score more than 3 * participants that wonn't be able to read ,write and willing to give consent.

Keywords: azadirachta indica gingival index herbal mouthwash tooth sensitivity
clinical efficacy and safety of minimally invasive glaucoma surgery on primary angle closure glaucoma

Conditions: Glaucoma, Angle-Closure

Summary: to evaluate the clinical efficacy (intraocular pressure reduction , success rate, the number of antiglaucoma medication) and safety of ab interno trabeculectomy (ait) with trabectome in chinese pacg .

a randomized, single blind, positive parallel control study method was used.this prospective case series will recruit 246 chinese poag, 123 cases in the experimental group will receive ait treatment and 123 cases in the control group will receive trabeculectomy(trab) surgery.measurements of intraocular pressure(iop) , visual acuity, refraction, slit lamp examination of the anterior segment and fundus, optical coherence tomography(oct) to detect retinal nerve fiber layer thickness, macular thickness, visual field, gonioscopy and ultrasonic biological microscopy (ubm) will be recorded.they will be followed up for 12 months. the main outcome is success rate of iop reduction and the other outcome are the number of antiglaucoma medication and complications .

Eligibility criteria:
inclusion criteria: * primary angle closure glaucoma (pacg) with visible trabecular meshwork from 90︒ to 180︒ on gonioscopy and iop couldn't be controlled ≤21mmhg with pilocarpine eye drop only. * willing to accept the antiglaucoma surgery * volunteer to participate in this study and be able to follow up on time * previous antiglaucoma filtering surgery or laser surgery(lpi, slt) and previous cataract surgery were not ruled out * exclusion criteria: * visual acuity lower than hm or central tubular visual field * corneal edema or large pterygium affecting the observation of anterior angle * the demarcation of the scleral process and trabecular meshwork is not clear on gonioscopy * new vessels on the iris surface or in the anterior angle chamber * the eye received surgery is the only eye with visual function, that is the contralateral eye is blind * requiring long-term use of anticoagulant drugs for systemic reasons * abnormal coagulation function * with specific clear scar physique * cannot participate in follow-up
physiotherapy exercises in patients with sternal instability after cardiovascular surgery

Conditions: Mediastinitis; Coronary Artery Disease; Cardiovascular Infections

Summary: sternal instability caused by mediastinitis is one of the most feared complications for cardiac surgery team for generating large commitments and functional damages to patients. biomechanically, the contraction of abdominal muscles such as transverse abdominal, produces forces that result in a "corset-like" action and anterior thoracic cage muscles too may assist in stabilizing the sternum. thus, strengthening the abdominal muscles might contribute to the recovery of functional aspects. the aim was to evaluate whether contraction and strengthening the abdominal muscles could improve lung function and respiratory muscle strength in patients with sternal instability.

sternal instability was confirmed by physical examination and confirmed by chest tomography. the data were collected before and after the 3-week period of intervention. sternal instability way assessed by the unstable sternal scale, graduated from zero to 4 points. the respiratory muscle strength was measured through manuvacuometry and the pulmonary function by the spirometry. pain was recorded by using a visual analog scale (0 -10); discomfort scale( 0-10) and identification of activities that cause pain and discomfort. patients underwent abdominal exercise protocol for three weeks once a day, lasting about 15 minutes followed by the physiotherapist.

Eligibility criteria:
inclusion criteria: * postoperative period of cardiovascular surgery by median sternotomy with sternal instability * written inform consent exclusion criteria: * chest tube * hemodynamic instability * neurological alteration * active infection

Keywords: sternal instability physical therapy respiratory muscle strength
adjuvant chemotherapy with docetaxel, capecitabine and cisplatin in patients with advanced gastric cancer: adjuvant dxp

Conditions: Resected Advanced Gastric Cancer

Summary: despite the improvement of surgical resection as primary curative treatment for gastric cancer, more than 70% of patients with stage iiib and iv disease undergoing radical primary tumor resection relapse and die within 5 years. therefore, there is an urgent need to further improve the treatment for gastric cancer in this population. recently reported phase iii study comparing capecitabine/cisplatin (xp) versus 5-fu/cisplatin (fp), xp showed better activity and tolerability compared with fp. to improve treatment outcomes of xp chemotherapy, the investigators performed a phase i-ii study of docetaxel, capecitabine and cisplatin in advanced gastric cancer (agc). phase i-ii study of docetaxel, capecitabine and cisplatin as first-line chemotherapy in advanced gastric cancer (kang et al, proc am soc clin oncol 22,328.2003). the docetaxel/capecitabine/cisplatin (dxp) chemotherapy was highly active for the 1st-line chemotherapy of agc. these findings and experience encourages the investigators to design the adjuvant trial of dxp chemotherapy in patients with resected gastric cancer. the aim of this study is to assess the efficacy and safety of adjuvant dxp in this patient population.

previous in phase ii study of docetaxel, capecitabine and cisplatin,total 40 pts with measurable disease, median 6 cycles of chemotherapy, there were 4 confirmed complete responses (crs) and 23 confirmed partial responses (prs), with the overall response rate of 67.5% (95% confidence interval, 52.7 \~ 82.3) in intention-to-treat analysis. ten patients underwent surgical resection after 4 \~ 9 cycles of chemotherapy. four pathologic crs were identified. with a median follow-up of 14 months (range, 1 to 28), median time to progression was 7.7 months, and median overall survival was 16.9 months. the dxp chemotherapy was highly active for the 1st-line chemotherapy of agc (kang et al, proc am soc clin oncol 22,328.2003).

Eligibility criteria:
inclusion criteria: * histologically or cytologically documented gastric adenocarcinoma * age 18 -70 * eastern cooperative oncology group (ecog) performance status 0-1 * pathologic stage iiib or iv * complete resection (r0 resection) exclusion criteria: * other tumor type than adenocarcinoma * r1 or r2 resection * presence of distant metastasis * gastric outlet obstruction or intestinal obstruction * evidence of gastrointestinal bleeding * other serious illness or medical conditions

Keywords: resected advanced gastric cancer stage iiib and iv
physical activity and neuropsychological outcomes in a cancer population

Conditions: Cognitive Dysfunction; Breast Cancer Survivors

Summary: many cancer survivors experience treatment-related impairments in mental abilities such as memory, attention, and concentration (known as cognition). research indicates that physical activity can improve cognition in healthy adults; however, little is known about whether physical activity can improve cognition among cancer survivors. this study will test whether a physical activity intervention results in improvements in cognition among breast cancer survivors, which may lead to interventions to improve cognition.


Eligibility criteria:
inclusion criteria: * breast cancer survivors; diagnosed at stage 1, 2, or 3 less than 5 years ago - * not scheduled for or currently undergoing chemotherapy; sedentary, defined as engaging in less than 60 minutes of moderate to vigorous physical activity each week * accessible geographically and by telephone * have access to the internet * endorse experience difficulties with thinking abilities * in addition, participants on adjuvant therapy (e.g., tamoxifen or aromatase inhibitors) must be able and willing to remain on that treatment for the 3-month intervention period to prevent confounding of biomarker concentrations by treatment. exclusion criteria: * history of coronary heart disease, diabetes, stroke, orthopedic conditions that limit mobility, or any other serious medical condition that could make it potentially unsafe to be in an unsupervised physical activity intervention * other primary or recurrent invasive cancer within the last 10 years (other than nonmelanoma skin cancer or carcinoma of the cervix in situ) * unable to commit to a 3-month intervention schedule; any condition that, in the investigators' judgment, would contraindicate increased physical activity or otherwise interfere with participation in the trial * unable to provide a blood sample at the baseline measurement visit * unable to speak and read english.
capturing outcomes of clinical activities performed by a rounding pharmacist practising in a team environment

Conditions: Heart Failure, Congestive; Pulmonary Disease, Chronic Obstructive; Pneumonia; Diabetes Mellitus, Type 2; Coronary Arteriosclerosis

Summary: we, the researchers, propose to link a clinical pharmacist with an internal medicine or family medicine team to provide pharmaceutical care to all patients assigned to the team. the hypothesis is that through this team based approach, pharmacists will act as a resource for providing pharmacotherapeutic advice during the drug therapy decision making process and promote optimal drug use by identifying and resolving actual and potential drug related problems. this study is designed to test this hypothesis, by assessing the impact of this intervention on evidence based, quality of drug therapy indicators, for patients admitted with heart failure (hf), chronic obstructive pulmonary disease (copd), community acquired pneumonia (cap), type 2 diabetes mellitus (t2dm), and stable coronary artery disease (cad).

the overall goal of the collaborate study is to improve processes of care and patient outcomes by optimizing drug therapy via a hospital pharmacy practice model that integrates clinical pharmacists into the patient care team. the intervention consists of a clinical pharmacist assigned to the patient care team for the purpose of providing proactive clinical pharmacy services. the study pharmacist will be available during normal office hours 5 days per week to provide clarification of the patient's medication history, identify and resolve actual and potential patient specific drug related problems/issues, participate in patient care rounds, provide drug information to the patient care team, provide patient education and discharge medication counselling, and provide physician and/or nursing staff education. the anticipated pharmacist to patient ratio is approximately 1:20. control patients will receive usual care. usual care consists of reactive clinical pharmacy services (i.e. drug related issues identified as orders are received, or by patient profile review) provided by a ward based, not team based, clinical pharmacist.

Eligibility criteria:
inclusion criteria: * consecutive patients \> 18 years of age admitted to participating internal and family medicine teams during the 1 year study period will be eligible to receive the pharmacist intervention. for the purposes of data analysis, patients with a most responsible or primary diagnosis of hf, copd, cap, t2dm, and cad will be included. exclusion criteria: * residence outside the capital health catchment * admitted for ≤ 2 days * palliative care * transferred to another team

Keywords: drug therapy hospitals, teaching hospitals, community interprofessional relations patient care team pharmacists pharmacy service, hospital comparative study hospitalization
glycemic index and cvd: a crossover feeding study

Conditions: Obesity

Summary: this study will compare the physiological effects of two isoenergetic, nutrient-controlled diets that differ in glycemic index. the diets will be studied in obese adults in a 10-day crossover feeding trial.

this study will compare the physiological effects of two isoenergetic, nutrient-controlled diets that differ in glycemic index. the diets will be studied in obese male adults in a 10-day crossover feeding trial. hypothesis: obese subjects will show improvements in clinical endpoints associated with risk for diabetes and cardiovascular disease (cvd) after consuming a controlled low (compared to high) glycemic index diet for 10 days. 1º endpoint: insulin sensitivity as measured by the modified frequently sampled intravenous glucose tolerance test (fsivgtt). 2º endpoints: cvd risk factors; postprandial studies of oxidative stress; thermic effect of food.

Eligibility criteria:
inclusion criteria: * age 18 to 35 years * male * bmi ≥ 27 ≤45 kg/m2 * willingness to refrain from alcohol and caffeinated beverage consumption for duration of study exclusion criteria: * major medical illness * an abnormal screening laboratory test * taking any prescription medications that might affect body weight * current smoking (1 cigarette during any of the last 7 days) * consuming special diets

Keywords: obesity glycemic index insulin resistance cardiovascular disease diabetes
the study of pharmacokinetics of levetiracetam in patients undergoing intermittent hemodialysis

Conditions: Seizures

Summary: levetiracetam (lev) is one of second-generation antiepileptic drugs that has been used to treat partial and generalized epilepsy. lev is eliminated from the systemic circulation by renal excretion. therefore, patients with renal impairment may experience a reduced drug excretion and increased adverse drug reactions. moreover, patients with end-stage renal disease who need dialysis may experience low serum lev concentration because of drug loss via dialysis. lev loss via dialysis can cause low serum level of lev that insufficient for seizure control. the present study was aimed to evaluate pharmacokinetics of lev in patients undergoing 4 hour-intermittent hemodialysis (ihd). the results of the study may benefit to determine the appropriate lev initial dose and supplemental dose for patients undergoing ihd.


Eligibility criteria:
inclusion criteria: 1. patients who were at least 18 years old. 2. patients who were diagnosed with seizure. 3. patients who were undergoing intermittent hemodialysis and were treated with intravenous levetiracetam not less than 2 days exclusion criteria: 1. patients who were pregnant or lactating 2. patients who were treated with intravenous levetiracetam more than once a day 3. patients who were undergoing sustained low efficiency dialysis (sled) 4. patients who have intermittent dialysis duration less than 3 hours

Keywords: levetiracetam pharmacokinetics hemodialysis
compare tolerability of an overnight switch to gradual switch between two different forms of depakote

Conditions: Epilepsy; Behavioral Disturbance

Summary: the hypothesis is that the characteristics of extended release depakote will allow overnight conversion of immediate release to extended release form of depakote. this has been tested successfully in younger patients but not in individuals over the age of 60. we will include individuals between 60 and 80 years old.

twenty patients will be randomily assigned to convert overnight (10 pts) or over six days (10 pts). side effects will be formally evaluated by the uku side effect rating scal which will be done 7 days before conversion (day -7), the day of conversion (day 0)and then at the start of days +2, +7 and +14. this investigator conducting the evaluation will be blinded to the conversion status of the patient. secondary measures to be obtained will be a quality of life measure (qolie-89) on day 0 and +14. plasma samples will be obtained on day 0 and +14 before dosing for total and free valproic blood level.

Eligibility criteria:
inclusion criteria: * 60 yo and older on stable dose of valproate (depakote dr) exclusion criteria: * unstable neurolgical, medical or psychiatric disorder

Keywords: tolerability depakote dr depakote er elderly conversion